AP
MRK icon

Antipodes Partners’s Merck MRK Stock Holding History

Antipodes Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173M Sell
1,441,266
-134,545
-9% -$15.5M 3.34% 5
2025
Q4 		$166M Sell
1,575,811
-95,741
-6% -$8.99M 3.48% 6
2025
Q3 		$140M Sell
1,671,552
-142,708
-8% -$11.8M 3.15% 12
2025
Q2 		$144M Sell
1,814,260
-153,710
-8% -$12.2M 4.45% 7
2025
Q1 		$177M Buy
1,967,970
+119,339
+6% +$11.1M 5.53% 5
2024
Q4 		$184M Buy
1,848,631
+272,815
+17% +$28.1M 6.39% 4
2024
Q3 		$179M Sell
1,575,816
-99,830
-6% -$11.9M 6.2% 3
2024
Q2 		$207M Sell
1,675,646
-213,659
-11% -$27.5M 7.54% 1
2024
Q1 		$249M Sell
1,889,305
-285,599
-13% -$35.2M 7.88% 1
2023
Q4 		$237M Sell
2,174,904
-95,095
-4% -$9.87M 7.41% 1
2023
Q3 		$237M Buy
2,269,999
+520,841
+30% +$56.1M 7.61% 1
2023
Q2 		$202M Sell
1,749,158
-107,402
-6% -$12.2M 6.97% 1
2023
Q1 		$198M Buy
1,856,560
+1,121
+0.1% +$121K 6.85% 1
2022
Q4 		$206M Sell
1,855,439
-409,457
-18% -$41.9M 7.38% 1
2022
Q3 		$195M Buy
2,264,896
+316,431
+16% +$28.2M 7.83% 1
2022
Q2 		$178M Sell
1,948,465
-239,177
-11% -$21.2M 7.4% 1
2022
Q1 		$179M Buy
2,187,642
+222,174
+11% +$17.5M 6.36% 2
2021
Q4 		$151M Buy
1,965,468
+62,956
+3% +$5.01M 5.41% 7
2021
Q3 		$143M Sell
1,902,512
-154,947
-8% -$11.8M 4.88% 6
2021
Q2 		$160M Sell
2,057,459
-72,933
-3% -$5.42M 5.77% 3
2021
Q1 		$157M Buy
2,130,392
+108,406
+5% +$8M 6.35% 3
2020
Q4 		$158M Buy
2,021,986
+202,783
+11% +$15.5M 6.86% 3
2020
Q3 		$144M Sell
1,819,203
-161,405
-8% -$12.6M 6.6% 4
2020
Q2 		$146M Buy
1,980,608
+39,093
+2% +$2.94M 6.62% 3
2020
Q1 		$143M Buy
+1,941,515
New +$153M 7.46% 3
2019
Q4 		– Sell
-1,853,247
Closed -$149M – 33
2019
Q3 		$149M Buy
1,853,247
+317,954
+21% +$25.5M 7.1% 3
2019
Q2 		$123M Buy
+1,535,293
New +$118M 5.64% 8

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Antipodes Partners's MRK Position: Q1 2026 in Review

Antipodes Partners reduced its Merck (MRK) stake by 8.5% in Q1 2026, selling an estimated $15.5M and leaving 1,441,266 shares worth $173M. The position accounts for 3.34% of the portfolio, ranked #5.

Antipodes Partners first reported a position in MRK in Q2 2019 and has held it in 27 quarters since. The position peaked at $249M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Antipodes Partners held 1,441,266 shares of Merck worth $173M as of Q1 2026.
  • Antipodes Partners sold 134,545 Merck shares in Q1 2026, an estimated $15.5M.
  • Merck made up 3.34% of Antipodes Partners's portfolio in Q1 2026, its #5 holding.
  • Antipodes Partners first reported a position in Merck in Q2 2019 and has held it in 27 quarters since.
  • Antipodes Partners's Merck position peaked at $249M in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.